Alaunos Therapeutics, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
Alaunos Therapeutics (market cap ~$9.6M) is acquiring Velaris Therapeutics in a reverse merger. Velaris valued at $200M, Alaunos at $15M (pre-cash). Merger consideration: 33,054 shares Parent Series C Preferred Stock to common holders + 105,286 shares Series B Preferred Stock to preferred holders (each convertible 1:1000 to common stock, subject to stockholder approval). Concurrent $250M-$350M financing from lead investors. Transaction closes immediately via two-step merger structure; post-closing, combined entity rebrands to Velaris Therapeutics, Inc.
Why this rating
Transformational M&A for $9.6M company: acquires $200M-valued biotech platform, raises $250M+ capital, enables major operations expansion. Highly dilutive but capital-transforming for near-bankrupt shell.
Tradability signal
NO TRADE
No trade: already up 13.2% on the news and the fade evidence is too weak. Similar past filings (227 in this cell) moved +0.01% in the called direction over 4 hrs; shrunk for sample size that's a +0.01% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.74 ▲ 4.51% | at our read · unknown $1.67 | +10 min · unknown $1.84 ▲ 10.45% | +30 min · unknown $1.68 ▲ 0.90% | +1 hr · unknown $1.83 ▲ 10.21% | +4 hrs · unknown $3.23 ▲ 93.69% |
The stock had already moved -4.32% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.